Loading...
The past two decades have seen disparate estimates of colorectal cancer (CRC) risk in patients with inflammatory bowel disease (IBD). Researchers generally agree that risk is increased by longer duration of disease, greater extent of disease (i.e., panulcerative colitis; involvement of >1/3 of the colon in Crohn disease), family history of CRC, and concomitant primary sclerosing cholangitis (PSC). Alternately, risk appears to be reduced by modern therapies that minimize inflammation, particularly immunomodulators and perhaps also 5-aminosalicylates and anti–tumor necrosis factor agents. Now, two new studies have addressed the incidence of CRC in patients with IBD.
Jess and colleagues, using data from Danish national registries, examined tren…